Review of neoadjuvant chemotherapy characteristics in advanced epithelial ovarian cancer: experience from two cancer centers

Background: This study aimed to review the characteristics and survival of patients with Advanced Epithelial Ovarian Cancer undergoing neoadjuvant chemotherapy (NACT) and the impact of timing of surgery and post-operative adjuvant chemotherapy (CCT). Methods: Retrospective multicentre study, of patients with an initial diagnosis of advanced high-grade epithelial ovarian carcinoma, considered inoperable at diagnosis and treated with NACT. Results: Eighty-six patients were analyzed. Fifty-seven underwent surgery, with significantly higher median overall survival (mOS) versus those who were never operated. The percentage of complete surgery (R0) was 74%, with a median progression-free survival (mPFS) of 45 months and mOS of 67 months versus mPFS of 27 months and mOS of 28 months in patients with residual disease. Of the operated patients, 21 underwent 3–4 cycles of NACT and 36 5–6 cycles of NACT, with a mOS of 64 months and 38 months respectively. Patients with almost complete/complete NACT response had significantly improved PFS and OS compared with patients with partial/minimal/absent response. Twenty-two patients underwent 2–3 cycles CCT with no significant differences in terms of PFS or OS. COX regression showed that both the increase in time between NACT and surgery and the chemotherapy response score are related to the risk of death. Conclusions: Complete surgery and Chemotherapy Response Score (CRS) were the most important prognostic factors for survival in this population. The use of CCT showed no advantage in survival outcomes. Prospective studies are needed to evaluate new therapeutic strategies for patients with inoperable ovarian cancer at diagnosis.

Ovarian neoplasms; Neoadjuvant therapy; Adjuvant chemotherapy

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA - A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Annals of Oncology. 2019; 30: 672–705.

[3] NCCN Guidelines Version 3. 2021 Ovarian Cancer. Retrieved from ovarian.pdf (nccn.org).

[4] Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. an exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology. 2007; 106: 69–74.

[5] Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology. 2012; 19: 4059–4067.

[6] Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine. 2010; 363: 943–953.

[7] Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015; 386: 249–257.

[8] Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer. 2016; 64: 22–31.

[9] Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. European Journal of Cancer. 2016; 59: 22–33.

[10] Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. Journal of Clinical Oncology. 2015; 33: 2457–2463.

[11] Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. European Journal of Cancer. 2016; 60: 49–58.

[12] Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. Journal of Clinical Oncology. 2010; 28: 3570–3576.

[13] Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Annals of Oncology. 2016; 27: 1449–1455.

[14] Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, et al. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? Journal of Gynecologic Oncology. 2019; 30: e81.

[15] Akladios C, Baldauf J, Marchal F, Hummel M, Rebstock L, Kurtz J, et al. Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?Oncology. 2016; 91: 331–340.

[16] Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecologic Oncology. 2014; 135: 223–230.

[17] Xu X, Deng F, Lv M, Chen X. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Archives of Gynecology and Obstetrics. 2017; 295: 451–458.

[18] du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospec-tively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO- OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009; 115: 1234–1244.

[19] SPG. Cancro Ginecológico - Consensos Nacionais 2020. 2020. Available at: https://spginecologia.pt/wp-content/uploads/2021/07/spg-consenso-nacional-cancro-ginecologico-2020.pdf (Accessed: 27 May 2022).

[20] Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer. 2017; 70: 133–142.

[21] Garcia Garcia Y, De Juan A, Mendiola C, Barretina-Ginesta MP, Prat A, Santaballa A, et al. Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL). Journal of Clinical Oncology. 2017; 35: 5508–5508.

[22] Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A. Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial). International Journal of Gynecologic Cancer. 2021; 31: 1175–1178.

[23] Kanjanapan Y, Lheureux S, May T, Wilson MK, Bernardini M, Shaw PA, et al. Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): the NEO trial. Journal of Clinical Oncology. 2017; 35: TPS5608–TPS5608.

[24] Michaan N, Chong WY, Han NY, Lim MC, Park SY. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy. International Journal of Gynecologic Cancer. 2018; 28: 1676–1682.